BASF stock faces Evonik impasse after weekend talks

BASF and Evonik held high-level talks over the weekend, but the meeting did not produce a roadmap for formal takeover negotiations. Reuters reported on Monday, November 9, that the chief executives and chief financial officers of both companies met after Evonik rejected BASF's increased offer. The report said an Evonik spokesperson declined to comment.

The development adds a fresh strategic issue for investors weighing BASF's acquisition ambitions. Reuters said the improved proposal values Evonik at EUR 11.18 billion, or EUR 24 per share. Evonik had previously rejected BASF's EUR 22.15-per-share offer in September.

Evonik keeps its distance

Evonik's continued resistance leaves BASF without a clear route toward negotiations. The target has asked BASF to explain the rationale for its bid, but the companies have yet to establish a formal process.

The central question is whether BASF can demonstrate enough strategic and financial value to change Evonik's position. For BASF shareholders, a prolonged impasse could keep attention focused on capital allocation, deal discipline and the potential effect of an acquisition on the group's existing businesses.

BASF stock traded at 53.92 euros on Lang & Schwarz at 18:05 CET on Monday, November 9, 2026, 0.66 percent below the Xetra close of Friday, November 6. The move puts the takeover debate against a cautious market backdrop, without establishing a direct causal link between the talks and the share price.

Investor focus shifts to execution

The immediate investor test is whether BASF can turn its strategic case into a credible negotiation framework while preserving shareholder value. Until then, the Evonik approach remains an option under pressure rather than a defined transaction.

The German market environment is tracked through the DAX.

More developments on the takeover case are available in Reuters. More news and analyses on BASF stock.